McKesson Corporation vs Northrop Grumman Corporation — how do they compare? McKesson Corporation trades at $930 (market cap $108.46B), while Northrop Grumman Corporation trades at $483.6 (market cap $68.83B). The key difference: McKesson Corporation is the larger of the two by market cap, and Northrop Grumman Corporation pays the higher dividend (2.04%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Northrop Grumman Corporation for 81 Days on average.
| MCK | NOC | |
|---|---|---|
Market Cap | $108.46B | $68.83B |
Volume | 712,607 | 1,081,989 |
Sector | Health | Industrials |
52-Week High | $995.69 | $768.02 |
52-Week Low | $725.17 | $473.46 |
Typical Hold Time | 74 Days | 81 Days |
Enterprise Value | $115.00B | $82.81B |
Dividend Yield | 0.4% | 2.04% |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Northrop Grumman (NOC) trades at $473.46, down 2.0% on the day, reflecting a bearish technical signal amid recent contract loss news. The stock exhibits strong fundamentals with a P/E of 15.05, net income margin of 10.48%, and consistent earnings beats in recent quarters. Revenue growth is steady, supported by a record backlog, though the loss of the $20 billion Navy F/A-XX contract to Boeing introduces competitive pressure.
The outlook remains supported by robust defense budgets and key programs like the B-21 bomber, but investor sentiment is cautious near-term. Analyst consensus is bullish with a $600.62 price target, though technical indicators suggest potential near-term weakness. Risks include contract dependencies and macroeconomic shifts in defense spending.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →